Japanese journal of clinical oncology最新文献

{"title":"Implementation strategies for cancer rehabilitation in clinical practice: a Delphi study.","authors":"Nanako Hijikata, Nobuko Konishi, Noriatsu Tatematsu, Nanako Nishiyama, Kazuhiro Kojima, Daisuke Ito, Yoshitada Sakai, Ken Kouda, Akira Tanuma, Yasuyuki Takakura, Junichiro Inoue, Takeshi Kobayashi, Takuro Sakurai, Noriyo Sugimori, Kyoko Abe, Miho Kurihara, Tetsuya Tsuji","doi":"10.1093/jjco/hyag085","DOIUrl":"10.1093/jjco/hyag085","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to identify implementation strategies and determine priorities for establishing a seamless cancer rehabilitation delivery system based on consensus among multidisciplinary stakeholders.</p><p><strong>Methods: </strong>An online modified-Delphi study was conducted. A total of 100 stakeholders (healthcare professionals, researchers, cancer survivors, and members of patient support groups) with experience in cancer rehabilitation were invited. Participants selected the top three barriers to cancer rehabilitation in the first survey. In the second survey, the implementation strategy list was provided, and the effectiveness of each strategy was rated using a 4-point Likert scale. In the third survey, participants evaluated the impact and cost of successful implementation using a 4-point scale to determine priority.</p><p><strong>Results: </strong>Valid responses were obtained from 85 participants for the first survey, 64 for the second survey, and 59 for the third survey. Consensus was reached on all 35 implementation strategies as effective measures (agreement rate for each item ranged from 70.3% to 98.4%). Fourteen items were judged very effective. The assessment of priority considering impact and cost indicated that reinforcing multidisciplinary collaboration and improving access to information were high priorities.</p><p><strong>Conclusions: </strong>This study identified implementation strategies and priorities for cancer rehabilitation based on expert consensus. These findings demonstrate that improving inter- and intra- organizational processes is as crucial as institutional and structural enhancements. The identified strategies are expected to bridge the gap between evidence and clinical practice in Japan, contributing to the promotion of effective, continuous cancer rehabilitation delivery systems.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1052-1061"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of adjuvant breast radiotherapy on the risk and the survival of second primary lung cancer: a large population-based study.","authors":"Nan-Nan Ji, Xue-Yan Yang, Shao-Qing Xiao, Na Zhao, Wen-Li Su, Jun-Nv Xu, Ling Shao, Shu-Ning Li, Yue-Can Zeng","doi":"10.1093/jjco/hyag089","DOIUrl":"10.1093/jjco/hyag089","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to quantify the long-term risk of second primary lung cancer (SPLC) following adjuvant breast radiotherapy (RT) and to evaluate its clinical significance in determining the appropriate duration of lung cancer screening among breast cancer survivors.</p><p><strong>Methods: </strong>A total of 370 782 female patients who underwent loco-regional breast adjuvant RT after breast cancer surgery were included for analysis using the US SEER-9 Plus database from 1975 to 2018. Additionally, survival analyses were conducted to compare patients with SPLC following adjuvant breast RT with those with only first primary lung cancer (PLC). PLC patients, defined as those diagnosed with only primary lung cancer and no other malignancies throughout their lifetime, were derived from the same SEER database for the survival analysis, not from external published data.</p><p><strong>Results: </strong>SPLC diagnosed at least 5 years after breast cancer was observed in 5632 patients (1.52%), comprising 2630 patients (1.55%) in the RT cohort and 3002 patients (1.49%) in the non-radiotherapy cohort. RT was associated with an increased risk of SPLC (adjusted hazard ratio [HR], 1.28; 95% CI, 1.22-1.35; P < .001). The median overall survival time for SPLC after breast RT was longer than that for primary lung cancer (18.0 months [95% CI, 17.0-20.0] vs. 14.0 months [95% CI, 13.0-16.0], P = .008). The 10-year overall survival rate of the SPLC patients after breast RT was significantly higher than that of primary lung cancer (14.3% [95% CI, 12.6-16.2] vs. 13.1% [95% CI, 11.6-14.8], P = .008), with an HR of 0.92 (95% CI, 0.86-0.98, P = .008).</p><p><strong>Interpretation: </strong>RT for loco-regional breast cancer was associated with an increased risk of developing SPLC. Given this increased risk, routine screening for SPLC should be considered for this population, particularly within 5-15 years following breast cancer diagnosis.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1080-1087"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.","authors":"Shinya Watanabe, Yuto Matsushita, Yuya Oishi, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Takafumi Yanagisawa, Keiichiro Mori, Seitetsu Sugiyama, Kensuke Bekku, Lan Inoki, Shingo Toyoda, Takuhisa Nukaya, Ryoichi Maenosono, Kazumasa Komura, Motoo Araki, Kazutoshi Fujita, Kiyoshi Takahara, Haruhito Azuma, Toshiki Ito, Teruo Inamoto","doi":"10.1093/jjco/hyag079","DOIUrl":"10.1093/jjco/hyag079","url":null,"abstract":"<p><strong>Background: </strong>In the era of immuno-oncology (IO) combination therapy, prognostic tools for elderly patients with metastatic clear cell renal cell carcinoma (ccRCC) are lacking. This study aimed to identify prognostic factors in elderly patients and evaluate a novel risk model using the restricted mean survival time (RMST) and a decision curve analysis (DCA).</p><p><strong>Methods: </strong>We retrospectively analyzed 203 patients aged ≥70 years with metastatic ccRCC treated with first-line IO combination therapy. Independent prognostic factors for overall survival (OS) were identified. Beyond the hazard ratio, a RMST analysis with a 24-month truncation time quantified absolute survival differences between risk groups. Clinical utility was evaluated using DCA.</p><p><strong>Results: </strong>A multivariable analysis identified low body mass index, low Karnofsky performance status, elevated lactate dehydrogenase, low serum albumin, and liver metastases as independent prognostic factors. In the RMST analysis at 24 months, significant survival disparities were quantified. The intermediate- and poor-risk groups showed mean survival reductions of 1.92 and 6.27 months, respectively, from OS in the favorable-risk group. The model demonstrated a higher net benefit through DCA than the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) classification across a wide range of threshold probabilities for 24-month OS. The model's C-index (0.728) was higher than that of the IMDC classification (0.603).</p><p><strong>Conclusions: </strong>Our prognostic model for elderly patients provides a practical tool for clinical decision-making by visualizing time-based survival differences via RMST and demonstrating potential clinical utility in DCA.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1111-1118"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.","authors":"Tomonori Kanagawa, Ichiro Yonese, Takehiro Nakamura, Mai Shimizu, Rie Tanaka, Hajime Kido, Tsukasa Shinoda, Ken Sekiya, Takahiko Soma, Masahiro Toide, Masaya Ito, Ryoji Takazawa, Fumitaka Koga","doi":"10.1093/jjco/hyag078","DOIUrl":"10.1093/jjco/hyag078","url":null,"abstract":"<p><strong>Introduction: </strong>Seeding and implantation are major mechanisms of intravesical recurrence (IVR) following the radical nephroureterectomy (RNU) of upper tract urothelial carcinoma (UTUC). We herein hypothesized that bladder biopsies (BB) may increase the IVR risk by promoting implantation in injured bladder mucosa.</p><p><strong>Patients and methods: </strong>This retrospective study included 172 patients with UTUC with no history of bladder UC who underwent RNU between January 2010 and December 2024 at two institutions. The primary endpoint was the association between BB and IVR-free survival (IVRFS) after RNU. A directed acyclic graph (DAG) was generated to identify potential confounders and guide multivariable analysis, and sensitivity analyses using propensity score matching were performed.</p><p><strong>Results: </strong>Eighteen (10%) patients underwent BB prior to RNU due to a positive voided urine cytology finding and/or the presence of erythematous mucosa. Patients receiving BB had significantly shorter IVRFS than those without BB (3-year IVRFS rate: 14% vs. 69%; P < .001). On both DAG-guided and stepwise multivariable models, BB was independently associated with an increased IVR risk (hazard ratio: 2.55 and 4.00, respectively; both P < .005). In the propensity score-matched cohort, BB was also associated with a shorter IVRFS. Notably, IVR developed at the BB sites in 60% of the cases of IVR following BB.</p><p><strong>Conclusions: </strong>BB is likely to increase the IVR risk in patients undergoing RNU for UTUC by promoting tumor cell implantation. Avoiding BB may be prudent unless both urine cytology and cystoscopic findings are highly suspicious for bladder carcinoma.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1103-1110"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POU2F3 expression in lung squamous cell carcinoma: transcriptomic and immunohistochemical profiling with prognosis.","authors":"Suguru Mitsui, Naoe Jimbo, Hiroyuki Ogawa, Shinya Tane, Daisuke Hokka, Yoshitaka Kitamura, Yoshimasa Maniwa, Tomoo Itoh","doi":"10.1093/jjco/hyag077","DOIUrl":"10.1093/jjco/hyag077","url":null,"abstract":"<p><strong>Background: </strong>Lung squamous cell carcinoma (LUSC) lacks well-defined molecular targets. This study investigated the clinical and biological relevance of POU class 2 homeobox 3 (POU2F3), a tuft cell-associated transcription factor, in LUSC.</p><p><strong>Methods: </strong>RNA sequencing data of patients with LUSC from The Cancer Genome Atlas (TCGA cohort, n = 190) was analysed and compared to a cohort of surgically resected cases analyzed via immunohistochemistry (IHC cohort, n = 137). Prognostic impact was assessed via survival analyses. Transcriptomic features, pathway enrichment, and immune profiles were evaluated via differentially expressed gene analysis, Gene Set Enrichment Analysis, and CIBERSORTx.</p><p><strong>Results: </strong>High POU2F3 expression independently predicted poor overall survival in the TCGA cohort (HR = 2.06, 95% CI: 1.04-4.08, P = 0.039). In contrast, POU2F3 expression was not prognostic in the IHC cohort (P = 0.995). Morphologically, POU2F3-positive tumours were enriched for non-keratinizing and poorly differentiated subtypes. Transcriptomic analysis showed suppression of proliferation and immune-related pathways (FDR < 0.001), with suggestive enrichment of the TGF-β (FDR = 0.143) and p53 (FDR = 0.229) signaling pathways. On immune deconvolution, POU2F3-high tumours showed a nominal increase in activated dendritic cells, which did not withstand multiple testing correction. POU2F3 protein was detected in 12.4% of tumours and was significantly associated with p53 or RB1 abnormalities (single or double) (P = 0.028).</p><p><strong>Conclusions: </strong>POU2F3 marks a transcriptionally distinct, early-stage subtype of LUSC with keratinization-related features. Its prognostic relevance appears context-dependent and requires prospective validation in uniformly treated cohorts.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1062-1073"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).","authors":"Kota Kawabata, Fumiharu Ohka, Ryuta Saito, Tsuyoshi Onoe, Hideyuki Harada, Takashi Sasayama, Hideaki Yokoo, Yoshiki Arakawa, Junki Mizusawa, Noriko Mitome, Keita Sasaki, Haruhiko Fukuda, Yoshitaka Narita","doi":"10.1093/jjco/hyag090","DOIUrl":"10.1093/jjco/hyag090","url":null,"abstract":"<p><p>Primary central nervous system lymphoma (PCNSL) is an aggressive malignancy. Patients refractory to high-dose methotrexate-based induction therapy have an extremely poor prognosis. Although whole-brain radiotherapy (WBRT) is the standard salvage treatment and provides potent tumor control, early functional deterioration and late neurocognitive toxicity remain major concerns. A phase I/II trial on relapsed or refractory PCNSL demonstrated favorable efficacy and tolerability of tirabrutinib, a second-generation selective Bruton's tyrosine kinase inhibitor. Tirabrutinib's oral administration has enabled outpatient management. However, its clinical value for induction-refractory PCNSL remains uncertain. We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment. A total of 94 patients from 49 institutions will be enrolled over 4 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1031250645).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1145-1151"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS).","authors":"Tetsuya Sekita, Tomonori Akagi, Ryo Sadachi, Takumi Hasegawa, Hidefumi Shiroshita, Haruhiko Fukuda, Takeshi Suto, Akio Shiomi, Manabu Shiozawa, Shunsuke Tsukamoto, Yusuke Sano, Ryosuke Kita, Yukihide Kanemitsu, Masafumi Inomata","doi":"10.1093/jjco/hyag084","DOIUrl":"10.1093/jjco/hyag084","url":null,"abstract":"<p><p>Transverse colon cancer is traditionally treated with extended right hemicolectomy (EHC), which involves division of the middle colic, right colic, and ileocolic arteries, along with removal of the terminal ileum and right colon. Transverse colectomy (TC) is a limited resection removing only 10 cm of bowel on either side of the tumor, along with resection of the middle colic artery and regional lymphadenectomy. This approach may contribute to the preservation of bowel function without compromising oncologic adequacy. This multicenter, randomized, phase III trial is designed to evaluate the non-inferiority of TC compared with EHC in terms of relapse-free survival among patients with Stage II/III transverse colon cancer whose main feeding artery is the middle colic artery. In total, 510 patients will be enrolled across major Japanese centers over 5 years. The trial has been registered with the Japan Registry of Clinical Trials (jRCT1030240479).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1139-1144"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients.","authors":"Takaki Ichiyama, Takuma Narita, Yuya Sekine, Masanao Shinohara, Yohei Kawashima, Mizuki Kobayashi, Kazuyuki Numakura, Jotaro Mikami, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hatakeyama","doi":"10.1093/jjco/hyag087","DOIUrl":"10.1093/jjco/hyag087","url":null,"abstract":"<p><strong>Objectives: </strong>Clinical studies in muscle-invasive bladder cancer (MIBC) often enroll younger and fitter patients than those treated in routine practice, limiting generalizability. We developed a simple eligibility gap (EG) score to quantify baseline eligibility differences between clinical studies and real-world cohorts.</p><p><strong>Methods: </strong>Eight clinical studies and eight real-world datasets were analyzed. The EG score was based on three commonly reported determinants: age, Eastern Cooperative Oncology Group performance status (ECOG PS), and cisplatin eligibility, each scaled from 0 to 33.3 points (total range: 0-99.9). Higher scores indicate younger, fitter, and more cisplatin-eligible populations. Known-groups validity was assessed by comparing EG scores across prespecified study categories expected to differ in eligibility selectivity. Sensitivity analyses using alternative fixed weighting schemes and random-weight simulations were performed to examine score robustness.</p><p><strong>Results: </strong>Baseline characteristics differed between clinical studies and real-world cohorts. Trial populations were generally younger, had better ECOG PS, and showed higher cisplatin eligibility than real-world cohorts. EG scores followed the expected ordering across prespecified study categories, with the highest values in cisplatin-fit trials (86), intermediate values in real-world cohorts (66), and the lowest values in cisplatin-unfit/refusal trials (44), consistent with known-groups validity. Domain-specific analyses showed larger differences in age and cisplatin eligibility than in ECOG PS. Across alternative weighting scenarios, rank correlations with the equal-weight model remained high (ρ = 0.976-0.994), and the expected category-level ordering was preserved.</p><p><strong>Conclusions: </strong>The EG score describes eligibility differences between clinical studies and real-world MIBC populations and may aid interpretation of trial evidence across heterogeneous populations.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1119-1127"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we missing an important point? Risk factors for intraoperative complications and additional procedures when performing post-chemotherapy RPLND for testicular tumors.","authors":"Mesut Altan, Hakan Keskin, Sertac Yazici","doi":"10.1093/jjco/hyag088","DOIUrl":"10.1093/jjco/hyag088","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the risk factors associated with additional intraoperative procedures during post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with advanced germ-cell tumors.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed the data of 206 patients who underwent PC-RPLND for advanced germ-cell tumors between January 1990 and December 2022. Additional intraoperative procedures were defined as surgical interventions necessitated by injuries to intestinal, ureteral, major vascular, or renal vascular structures, as well as planned en-bloc resections. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of these additional procedures.</p><p><strong>Results: </strong>A total of 67 additional procedures were performed in 56 patients (27.2%). The most frequent interventions were vascular procedures (aortic, caval, or renal vessel repairs), occurring in 40 patients (19.4%). This was followed by en-bloc nephrectomy in 10 (4.9%), intestinal injury repair in 9 (4.4%), and ureteral injury repair in 8 (3.9%) patients. Multivariate analysis revealed that tumor size at initial diagnosis (P < .05) and the presence of viable tumor in the pathology specimen (P < .05) were independent risk factors for requiring additional intraoperative procedures.</p><p><strong>Conclusion: </strong>Tumor size at the time of initial diagnosis, rather than preoperative size, serves as a significant predictor for additional surgical procedures during PC-RPLND. Surgical planning should account for initial tumor burden and the likelihood of viable disease to optimize perioperative outcomes.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1128-1132"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering prostate cancer screening: limitations of net survival and the primacy of overall survival as an endpoint.","authors":"Takeshi Takahashi","doi":"10.1093/jjco/hyag075","DOIUrl":"10.1093/jjco/hyag075","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1152-1153"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147948533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}